Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly increases Chinese sales by 26 per cent

Eli Lilly says its has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole

US-based pharmaceutical company Eli Lilly has said it has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole.

The company added that it expected to become the tenth largest company in the global pharmaceutical market by 2010. China is expected to become the seventh largest pharmaceutical market in 2012 and the second largest in 2020.

Lilly says it will introduce five drugs to the Chinese market in 2007 and an additional fifteen drugs over the next five years. The company signed an agreement with Hutchison Whampao, a drug development unit owned by Li Ka-shing, for the development of western drugs for treating cancer and inflammation.

18th September 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...